Anti-NY ESO-1 mTCR PBL

Anti-NY ESO-1 mTCR PBL is a form of adoptive cell therapy that uses genetically modified T cells to target cancer cells expressing the NY-ESO-1 antigen. This therapy represents an important advancement in cancer immunotherapy, particularly for treating tumors that express the NY-ESO-1 cancer testis antigen. ## Description Anti-NY ESO-1 mTCR PBL consists of peripheral blood lymphocytes (PBL) that have been transduced with a retroviral vector expressing a murine T-cell receptor (mTCR) that specifically targets the NY-ESO-1 antigen[4]. NY-ESO-1 is a cancer testis antigen expressed in various prevalent tumors but not in normal tissues (except for the testes), making it an ideal target for cancer immunotherapy[1][2]. The therapy works by collecting a patient's white blood cells through leukapheresis, genetically modifying them in the laboratory to express the anti-NY-ESO-1 T cell receptor, expanding them to large numbers, and then reinfusing them back into the patient[3]. This process creates a large population of T cells with defined antigen specificity that can recognize and attack NY-ESO-1-expressing cancer cells[1]. Clinical trials have shown that this approach can lead to tumor shrinkage in some patients with NY-ESO-1 expressing cancers[3]. The treatment is typically administered along with conditioning chemotherapy (such as cyclophosphamide and fludarabine) and aldesleukin (IL-2) to enhance the effectiveness of the transferred cells[4]. ## Development and Clinical Application The National Cancer Institute (NCI) Surgery Branch developed this experimental therapy for treating patients with cancers that express the NY-ESO-1 molecule[3]. Previous studies using anti-ESO-1 gene therapy showed tumor shrinkage in approximately half of the treated patients[3]. The therapy is being evaluated in clinical trials for patients with various NY-ESO-1 expressing cancers. Patients typically undergo a comprehensive workup including history, physical examination, scans, and laboratory tests before proceeding with leukapheresis to obtain white blood cells for modification[3]. After treatment, patients are monitored with regular follow-up visits that include physical examinations, side effect assessments, laboratory tests, and scans to evaluate treatment response[3]. ## Mechanism of Action The anti-NY-ESO-1 mTCR recognizes the NY-ESO-1 antigen presented on the cell surface by major histocompatibility complex (MHC) class I molecules[2]. When the modified T cells encounter cancer cells expressing NY-ESO-1, they become activated, release cytokines (such as interferon-γ), and directly kill the target cells[1]. The murine TCR used in this therapy was designed to have high avidity for antigen recognition, with studies showing recognition of peptide-pulsed cells at concentrations as low as 0.1 ng/ml[1]. The modified T cells maintain TCR expression in both short-term and long-term culture, with expression efficiency ranging from 50-90% 7-11 days post-stimulation[1]. This approach represents a promising frontier in cancer immunotherapy, particularly for advanced stages of disease where NY-ESO-1 expression is common[2].

Other names

anti-NY ESO-1 T cell receptor therapyNY-ESO-1 TCR therapyNY-ESO1 TCR therapyNY-ESO 1 TCR therapy